NIOSHTIC-2 Publications Search

Sarcoidosis.

Antonini JM

xPharm the comprehensive pharmacology reference. Enna SJ, Bylund DB, eds. Boston, MA: Elsevier Inc., 2008 Jan; :1-5

https://doi.org/10.1016/B978-008055232-3.60788-3

20045751

Sarcoidosis was first identified over one hundred years ago by two dermatologists, Dr. Jonathan Hutchinson in England and Dr. Caesar Boeck in Norway. It is a multi-organ, inflammatory disease characterized by the formation of granulomas. The cause of the disease is unknown. Sarcoidosis can appear suddenly and disappear spontaneously. In some cases, it can develop gradually with symptoms that can last a lifetime, leading to the eventual formation of fibrosis in the affected tissues. Sarcoidosis is the most common of the fibrotic lung disorders. <a href="http://dx.doi.org/10.1016/B978-0-12-801238-3.05290-9"target="_blank">Updated by: http://dx.doi.org/10.1016/B978-0-12-801238-3.05290-9</a>

Immune-system-disorders; Immune-reaction; Organs; Body-regions; Fibrosis; Tissue-disorders; Physiological-disorders; Physiological-function; Lung-disorders; Lung-fibrosis; Pulmonary-disorders; Lymph-nodes; Lung-tissue; Author Keywords: Antigenic; Corticosteroids; Fibrosis; Granuloma; Immunologic; Inflammatory disease; Methotrexate; Pulmonary; t-lymphocytes; Tumor necrosis factor-a

20080108

Chapter

Enna SJ; Bylund DB

2008

9780080552323

HELD

xPharm the comprehensive pharmacology reference

WV